What is HC Wainwright’s Forecast for PVLA FY2026 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Investment analysts at HC Wainwright reduced their FY2026 EPS estimates for shares of Palvella Therapeutics in a research report issued to clients and investors on Wednesday, April 1st. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($4.41) per share for the year, down from their prior forecast of ($3.28). HC Wainwright currently has a “Buy” rating and a $270.00 target price on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2027 earnings at ($3.76) EPS, FY2028 earnings at $2.08 EPS, FY2029 earnings at $9.00 EPS and FY2030 earnings at $22.29 EPS.

PVLA has been the subject of several other research reports. TD Cowen reiterated a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Chardan Capital upped their target price on Palvella Therapeutics from $210.00 to $240.00 and gave the company a “buy” rating in a research report on Tuesday. Raymond James Financial reaffirmed a “strong-buy” rating and set a $193.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Mizuho increased their price target on Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Finally, Stifel Nicolaus set a $250.00 price target on Palvella Therapeutics in a report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $198.07.

Palvella Therapeutics Stock Performance

NASDAQ PVLA opened at $123.46 on Friday. The firm’s fifty day simple moving average is $107.19 and its two-hundred day simple moving average is $92.55. The firm has a market capitalization of $1.77 billion, a P/E ratio of -33.28 and a beta of -0.21. Palvella Therapeutics has a 12-month low of $18.23 and a 12-month high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Tuesday, March 31st. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.13).

Institutional Trading of Palvella Therapeutics

Several large investors have recently added to or reduced their stakes in PVLA. Group One Trading LLC increased its holdings in shares of Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the period. Archer Investment Corp acquired a new stake in shares of Palvella Therapeutics during the third quarter worth about $28,000. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics during the third quarter worth about $36,000. China Universal Asset Management Co. Ltd. purchased a new stake in Palvella Therapeutics in the fourth quarter valued at approximately $167,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Palvella Therapeutics in the fourth quarter valued at approximately $238,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Insider Transactions at Palvella Therapeutics

In related news, Director George M. Jenkins acquired 4,000 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were purchased at an average cost of $125.00 per share, with a total value of $500,000.00. Following the completion of the acquisition, the director directly owned 187,171 shares of the company’s stock, valued at $23,396,375. This represents a 2.18% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total value of $507,592.98. The SEC filing for this sale provides additional information. Insiders own 20.50% of the company’s stock.

Key Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: HC Wainwright sharply raised long‑term EPS forecasts and reiterated a Buy rating with a $270 target — FY2028 to $2.08 (from -$1.84), FY2029 to $9.00 (from $2.19) and FY2030 to $22.29 (from $11.56). These large upward revisions signal the firm expects material value creation farther out, which tends to support higher share valuations. MarketBeat HC Wainwright Coverage
• Positive Sentiment: Chardan Capital coverage noted an expectation the stock price will rise, adding an independent bullish voice that can amplify buying interest. Article Title
• Neutral Sentiment: HC Wainwright also published detailed 2026 quarterly forecasts (Q1 2026: -$0.89; Q2: -$1.02; Q3: -$1.19; Q4: -$1.30). These short‑term loss projections provide a clearer operating path but do not change the firm’s long‑term bullish stance. MarketBeat Q‑trends
• Negative Sentiment: HC Wainwright trimmed near‑term estimates — FY2026 EPS down to ($4.41) from ($3.28) and FY2027 to ($3.76) from ($3.43) — indicating a worse short‑term profitability outlook that can pressure sentiment for investors focused on near‑term results. MarketBeat Near‑term Cuts
• Negative Sentiment: Lifesci Capital lowered its FY2026 estimate to ($6.11) from ($4.49), a notably deeper loss projection that reinforces near‑term downside risk and highlights analyst disagreement on the timing of recovery. MarketBeat Lifesci Note

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.